🔥 Monday 5 October 2026 Mon, 5 Oct 2026

Moab Minerals has resumed trading after lodging an annual report that shows a smaller loss but a stark liquidity warning. The uranium explorer says it needs fresh capital, creditor support and lower costs to continue operating normally.

Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.

Clime Capital delivered a sharply stronger FY26 result, with after-tax profit rising to $10.3 million and dividends maintained. But KPMG qualified its audit after failing to obtain sufficient evidence for $36.2 million of unlisted unit trust valuations and related income and fees.

GBM Resources has extended high-grade gold mineralisation beyond the current resource boundaries at both the 309 and Lone Sister deposits in Queensland. A further 3,550 metres of assays remain pending ahead of a planned Twin Hills resource update.

OD6 Metals has secured A$6.92 million from institutional and sophisticated investors to advance drilling, bulk sampling and resource definition at its Quinn Fluorspar Project in Nevada. The funding also sets up a proposed rebrand to Adaven, but brings dilution and a substantial package of shareholder approvals.

Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.

Austral Resources’ proposed acquisition of Hammer Metals has cleared its first Federal Court hurdle, with ASIC registration of the Scheme Booklet and a shareholder vote now set for 9 November. The transaction still needs shareholder approval, a second Court hearing and other conditions before implementation.

PhosCo has extended mineralisation at its DOH prospect and made a new phosphate discovery at Sekarna North in Tunisia. The results are encouraging, but assays remain pending and the reported widths are reconnaissance-stage intersections rather than resource estimates.

Aspen Group delivered a stronger-than-expected first quarter, with net rental income up 16% and realised development profit nearly doubling to $7.9 million. The company maintained its FY27 targets, while warning that weaker economic conditions could disrupt development settlements.

PDI Gold has paired a strong September quarter with high-grade drilling beneath its Kiniéro pits, strengthening the case for further resource growth at Guinea’s producing gold operation. The results remain exploration-stage, but the company is preparing a 140,000-metre campaign for 2027.

Osmond Resources has secured the maximum €250,000 provisional grant in the first round of Spain’s national mineral exploration program, while preparing to start a 13-hole campaign at its Orión project. The company has also issued 85 million shares to retain its 80% interest in the project-owning vehicle.

Ingenia Communities has granted Warburg Pincus non-exclusive access to initial due diligence on its $5.25-per-security takeover proposal, bringing the rival approach into a more serious evaluation phase. The board has not endorsed the proposal and continues to progress its acquisition of Peet.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

FlexiRoam has onboarded one of Australia’s four major banks to offer complimentary global data roaming on premium rewards Mastercard cards. The live program is expected to generate about USD 140,000 a year under management’s current planning case, although there is no minimum revenue commitment.

Zenith Minerals has rejected an unsolicited $5 million capital-raising proposal from Aurenne, saying it is incomplete, difficult to implement and offers shareholders no direct consideration. The board has kept its recommendation of Forrestania Resources’ takeover offer unchanged.

IODM has secured the first 15 university commitments in its planned 283-university US rollout, while revenue rose 10.2% despite a sharp fall in UK international student visa applications. The onboarding is not yet revenue, but the December-quarter target gives investors a clear execution test.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

EQT Infrastructure has reaffirmed its intention to pursue a takeover of Cleanaway at no less than its indicative offer price, clearing another hurdle in the non-binding process. The parties are now working towards an implementation deed, but a binding transaction remains uncertain.

CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.

Capricorn Metals produced 31,218 ounces of gold in the September quarter, while its Karlawinda expansion was completed on schedule and within budget. The enlarged operation is now running at 6.5 million tonnes a year, although the next test is converting that capacity into consistent production and costs.

Brightstar Resources has delivered broad and high-grade gold intercepts from final infill drilling at Bull Oak, including 167 metres at 2.07g/t gold and a 0.5-metre zone grading 265g/t. The results are intended to support an updated Mineral Resource and the Sandstone project’s pre-feasibility study, although neither has yet been released.

HealthCo Healthcare and Wellness REIT has signed binding agreements for new leases covering its remaining 10 Healthscope hospitals, subject to final approvals. The resolution allows HCW to reinstate quarterly distributions while reducing its largest tenant concentration from 57% to 31%.

Brazilian Critical Minerals has signed binding agreements to acquire 90% of a Brazilian magnesium sulphate producer, aiming to secure a key input for its Ema rare earth project. The strategy offers greater supply-chain control, but the plant requires restructuring and carries estimated legacy liabilities of R$15.3 million.

Kalgoorlie Gold Mining has identified multiple coherent gold-in-regolith anomalies across the first 225-hole aircore test of its LTZ Flexure target at Pinjin. The strongest exploration signal stretches up to 2km, but primary gold mineralisation at depth remains unconfirmed.